{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T12:02:07Z","timestamp":1789646527295,"version":"4.0.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,17]]},"DOI":"10.7759\/cureus.116411","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:06:46Z","timestamp":1789643206000},"source":"Crossref","is-referenced-by-count":0,"title":["Duodenal Ulcer Perforation Following Tirzepatide Injections for Weight Loss Management: A Case Report"],"prefix":"10.7759","author":[{"given":"Hayder","family":"Al-Azzawi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Joint Formulary Committee, 2024. Tirzepatide. (2024). Accessed. 24\/08\/26: https:\/\/bnf.nice.org.uk\/drugs\/tirzepatide\/."},{"key":"ref2","unstructured":"National Institute for Health and Care Excellence (NICE). Tirzepatide for managing overweight and obesity (TA1026). (2024). Accessed. 24\/08\/26: https:\/\/www.nice.org.uk\/guidance\/ta1026."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-025-04528-7","article-title":"Prevalence of use and interest in using glucagon-like peptide-1 receptor agonists for weight loss: a population study in Great Britain","volume":"24","author":"Jackson SE","year":"2026","unstructured":"Jackson SE, Brown J, Llewellyn C, Mytton O, Shahab L. Prevalence of use and interest in using glucagon-like peptide-1 receptor agonists for weight loss: a population study in Great Britain. BMC Med. 2026, 24:1. 10.1186\/s12916-025-04528-7","journal-title":"BMC Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.80671","article-title":"Acute duodenal ulcer perforation following tirzepatide treatment: a case report","volume":"17","author":"Hayashi M","year":"2025","unstructured":"Hayashi M, Hayashi K, Tsujigiwa Y, Uwafuji S, Sato M, Kobayashi Y. Acute duodenal ulcer perforation following tirzepatide treatment: a case report. Cureus. 2025, 17:e80671. 10.7759\/cureus.80671","journal-title":"Cureus"},{"key":"ref5","article-title":"Anatomy, abdomen and pelvis: duodenum","author":"Omole AE","year":"2026","unstructured":"Omole AE, Gogna S, Khorasani-Zadeh A. Anatomy, abdomen and pelvis: duodenum. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2026."},{"key":"ref6","article-title":"Duodenal perforation","author":"Amini A","year":"2023","unstructured":"Amini A, Lopez RA. Duodenal perforation. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2023."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/gut.52.2.186","article-title":"Risk factors for peptic ulcer disease: a population based prospective cohort study comprising 2416 Danish adults","volume":"52","author":"Rosenstock S","year":"2003","unstructured":"Rosenstock S, J\u00f8rgensen T, Bonnevie O, Andersen L. Risk factors for peptic ulcer disease: a population based prospective cohort study comprising 2416 Danish adults. Gut. 2003, 52:186-93. 10.1136\/gut.52.2.186","journal-title":"Gut"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/5584_2020_496","article-title":"Effects of GLP-1 and its analogs on gastric physiology in diabetes mellitus and obesity","volume":"1307","author":"Maselli DB","year":"2021","unstructured":"Maselli DB, Camilleri M. Effects of GLP-1 and its analogs on gastric physiology in diabetes mellitus and obesity. Adv Exp Med Biol. 2021, 1307:171-92. 10.1007\/5584_2020_496","journal-title":"Adv Exp Med Biol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2004.08.007","article-title":"Clinical endocrinology and metabolism. Glucose-dependent insulinotropic polypeptide\/gastric inhibitory polypeptide","volume":"18","author":"Meier JJ","year":"2004","unstructured":"Meier JJ, Nauck MA. Clinical endocrinology and metabolism. Glucose-dependent insulinotropic polypeptide\/gastric inhibitory polypeptide. Best Pract Res Clin Endocrinol Metab. 2004, 18:587-606. 10.1016\/j.beem.2004.08.007","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2337\/db21-0459","article-title":"GIP receptor agonism attenuates GLP-1 receptor agonist-induced nausea and emesis in preclinical models","volume":"70","author":"Borner T","year":"2021","unstructured":"Borner T, Geisler CE, Fortin SM, et al.. GIP receptor agonism attenuates GLP-1 receptor agonist-induced nausea and emesis in preclinical models. Diabetes. 2021, 70:2545-53. 10.2337\/db21-0459","journal-title":"Diabetes"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/434994-duodenal-ulcer-perforation-following-tirzepatide-injections-for-weight-loss-management-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:06:49Z","timestamp":1789643209000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/434994-duodenal-ulcer-perforation-following-tirzepatide-injections-for-weight-loss-management-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.116411","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,17]]}}}